Cellectis to open labs and offices in Manhattan

Published: 9-Apr-2015
Research & Development

Will support the development of smart drugs for cancer


Cellectis, a France headquartered gene-editing company, has established a subsidiary, Cellectis, Inc, in New York at the Alexandria Center for Life Science, located on Manhattan’s east side.

The 12,000ft2 (approximately 1,100m2) US headquarters includes research laboratories to support the development of the company's Chimeric Antigen Receptor T-cell (CAR-T) pipeline for the treatment of cancer, as well as other types of therapeutic indications. It will be officially opened on 16 April.

Dr André Choulika, Founder, Chief Executive and Chairman of Cellectis, said New York City is one of the fastest-expanding biotech hubs in the world and the Alexandria Center for Life Science is surrounded by renowned academic and medical institutions, leading commercial companies in the life sciences industry as well as a robust financial market.

Cellectis uses gene editing to produce CAR-T cells with unique qualities and features, including allogeneic or 'off-the-shelf' versions, which can be produced more efficiently and shipped to patients worldwide.

  • Companies:
  • Cellectis
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Read more
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Research & Development

Pfizer and Cellectis enter cancer immunotherapy collaboration

Partners will use Cellectis’ allogeneic CAR-T technology to develop cancer drugs
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

A hothouse for drug r&d

Growing vaccines in fertilised chicken eggs is expensive and time-consuming and involves educated guesswork regarding the strain of virus to be vaccinated against. In contrast, plants can be used to produce large quantities of vaccines on a much shorter timescale, and because the virus-like particles (VLPs) produced lack the core genetic material of the virus, they are non-infectious and unable to reproduce
Research & Development

Cellectis and Lonza reach significant bioresearch milestone

Removal of endogenous glutamine synthetase (GS) in Lonza’s proprietary host cell line will facilitate the creation of highly productive recombinant cell lines
Research & Development

Cellectis and VitamFero sign five-year licensing agreement

To develop vaccines against parasitic infection
Research & Development

Cellectis bioresearch sets up US subsidiary

Expands presence in North American life sciences market
Research & Development

Lonza and Cellectis Bioresearch sign r&d agreement

Cellectis to use meganucleases to deactivate the glutamine synthetase (GS) in Lonza\'s CHOK1SV
Subscribe now